Nakagawa K, Akikawa K, Matsubara M, Kubo M
J Clin Endocrinol Metab. 1985 Feb;60(2):306-10. doi: 10.1210/jcem-60-2-306.
The effect of dexamethasone on the GH response to GH-releasing hormone (GHRH) was studied in vivo in six patients with acromegaly as well as in vitro in monolayer cultures of GH-secreting pituitary tumor cells obtained from three of these patients. Oral administration of 9 mg/day dexamethasone for 2 days decreased plasma GH responses to iv injection of 100 micrograms GHRH-(1-44 amide) in all six patients. Blood glucose levels were significantly increased, while plasma somatomedin-C levels were significantly decreased by this regimen of dexamethasone treatment. On the other hand, 2-day pretreatment with 50 nM dexamethasone of monolayer cultures of pituitary adenoma cells potentiated GH release basally and/or in response to 100 pM to 1 nM GHRH in vitro. These results indicate that the potentiating action of 2-day treatment of dexamethasone in vitro is overwhelmed in vivo by some extra-pituitary action, probably on the central nervous system, of glucocorticoids in patients with acromegaly.
在六名肢端肥大症患者体内以及从其中三名患者获取的生长激素分泌型垂体肿瘤细胞单层培养物中进行体外研究,观察地塞米松对生长激素(GH)对生长激素释放激素(GHRH)反应的影响。对所有六名患者口服9毫克/天地塞米松,持续2天,可降低静脉注射100微克GHRH-(1-44酰胺)后血浆GH反应。该剂量地塞米松治疗使血糖水平显著升高,而血浆生长调节素C水平显著降低。另一方面,垂体腺瘤细胞单层培养物用50纳摩尔地塞米松预处理2天,在体外可增强基础GH释放和/或对100皮摩尔至1纳摩尔GHRH的反应。这些结果表明,地塞米松体外2天治疗的增强作用在肢端肥大症患者体内被糖皮质激素可能作用于中枢神经系统的某种垂体外作用所抵消。